Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Celgene Corporation |
---|---|
Information provided by: | Celgene Corporation |
ClinicalTrials.gov Identifier: | NCT00044382 |
To estimate the percent of patients with myelodysplastic syndromes (MDS) who experience erythroid response and the interval to response with daily treatment of 25 mg of CC-5013 .
Condition | Intervention | Phase |
---|---|---|
Myelodysplastic Syndrome |
Drug: CC-5013 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Open Label Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Responsible Party: | Celgene Corporation ( Deborah Ingenito ) |
Study ID Numbers: | CC-5013-MDS-501-001 |
Study First Received: | August 27, 2002 |
Last Updated: | February 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00044382 |
Health Authority: | United States: Food and Drug Administration |
Revimid CC5013 CC-5013 |
Myelodysplastic syndromes Preleukemia Precancerous Conditions Hematologic Diseases |
Myelodysplasia Myelodysplastic Syndromes Lenalidomide Bone Marrow Diseases |
Neoplasms Pathologic Processes Disease Antineoplastic Agents |
Therapeutic Uses Syndrome Pharmacologic Actions |